R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 51.88 CNY 1.63%
Market Cap: 5B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

R&G PharmaStudies Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Gross Profit
ÂĄ287m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Gross Profit
ÂĄ15.3B
CAGR 3-Years
25%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Gross Profit
ÂĄ3.9B
CAGR 3-Years
17%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Gross Profit
ÂĄ6.6B
CAGR 3-Years
18%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Gross Profit
ÂĄ2.5B
CAGR 3-Years
8%
CAGR 5-Years
15%
CAGR 10-Years
26%
W
WuXi XDC Cayman Inc
HKEX:2268
Gross Profit
ÂĄ559.6m
CAGR 3-Years
310%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 13%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Gross Profit?
Gross Profit
287m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Gross Profit amounts to 287m CNY.

What is R&G PharmaStudies Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 3Y
15%

Over the last year, the Gross Profit growth was 22%. The average annual Gross Profit growth rates for R&G PharmaStudies Co Ltd have been 15% over the past three years .

Back to Top